HomeCompareOSAGY vs PFE

OSAGY vs PFE: Dividend Comparison 2026

OSAGY yields 1.64% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $27.5K in total portfolio value· pulled ahead in Year 9
10 years
OSAGY
OSAGY
● Live price
1.64%
Share price
$51.10
Annual div
$0.84
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.1K
Annual income
$182.74
Full OSAGY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — OSAGY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSAGYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSAGY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSAGY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSAGY
Annual income on $10K today (after 15% tax)
$139.65/yr
After 10yr DRIP, annual income (after tax)
$155.33/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,164.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSAGY + PFE for your $10,000?

OSAGY: 50%PFE: 50%
100% PFE50/50100% OSAGY
Portfolio after 10yr
$35.8K
Annual income
$13,220.73/yr
Blended yield
36.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OSAGY
No analyst data
Altman Z
1.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSAGY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSAGYPFE
Forward yield1.64%6.13%
Annual dividend / share$0.84$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$22.1K$49.6K
Annual income after 10y$182.74$26,258.71
Total dividends collected$1.7K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OSAGY vs PFE ($10,000, DRIP)

YearOSAGY PortfolioOSAGY Income/yrPFE PortfolioPFE Income/yrGap
1$10,864$164.30$9,153$693.39+$1.7KOSAGY
2$11,792$166.82$8,593$849.25+$3.2KOSAGY
3$12,786$169.21$8,336$1,066.78+$4.5KOSAGY
4$13,853$171.48$8,437$1,384.80+$5.4KOSAGY
5$14,996$173.63$9,013$1,875.40+$6.0KOSAGY
6$16,221$175.66$10,306$2,680.72+$5.9KOSAGY
7$17,535$177.59$12,820$4,101.38+$4.7KOSAGY
8$18,941$179.40$17,673$6,826.70+$1.3KOSAGY
9← crossover$20,448$181.12$27,543$12,591.86$7.1KPFE
10$22,063$182.74$49,560$26,258.71$27.5KPFE

OSAGY vs PFE: Complete Analysis 2026

OSAGYStock

OSRAM Licht AG provides various lighting products and solutions worldwide. The company operates through three segments: Opto Semiconductors, Automotive, and Digital. It manufactures light-emitting diodes (LEDs) that are used in general lighting, automotive, consumer, and industrial applications; and infrared, laser, and optical sensors for the automotive, smartphone, wearable, general lighting, industrial lighting, and projection sectors, as well as lightings for plants. The company also develops and produces lamps and lighting systems for stages, cinemas, and studios; LED-based plant cultivation systems; lighting solutions for industrial and medical applications, such as high-intensity UV lamps and LED illumination for clothing; and automotive systems based on LED and laser technology, and other customer-specific system solutions. In addition, it develops, produces, and markets LED light engines and light management systems, as well as electronic ballasts, LED drivers, and LED modules. Further, the company is involved in the provision of products in the areas of architectural interior and exterior lighting, as well as professional interior lighting solutions. It provides its products under the OSRAM, Vixar, SYLVANIA, Traxon, e:cue, Digital Lumens, Fluence, Clay Paky, ADB Stagelight, OSRAM CONTINENTAL, LED Engin, and b,a,g, brands. The company was formerly known as Kyros A AG and changed its name to OSRAM Licht AG in November 2012. The company was founded in 1906 and is headquartered in Munich, Germany. OSRAM Licht AG operates as a subsidiary of ams AG.

Full OSAGY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OSAGY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSAGY vs SCHDOSAGY vs JEPIOSAGY vs OOSAGY vs KOOSAGY vs MAINOSAGY vs JNJOSAGY vs MRKOSAGY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.